Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience

Reshma Ramlal, MD, Sameh Gaballa, MD, Julianne Chen, Gabriela Rondon, MD, Betul Oran, MD, Sairah Ahmed, MD, Qaiser Bashir, MD, Katayoun Rezvani, MD, PhD, David Marin, MD, Amin M. Alousi, MD, Partow Kebriaei, MD, Muzaffar Qazilbash, MD, Chitra Hosing, MD, Uday R. Popat, MD, Elizabeth J Shpall, MD, Richard Champlin, MD, Stefan O. Ciurea, MD

Blood (2015) 126 (23): 3225.

https://doi.org/10.1182/blood.V126.23.3225.3225

Published: 2015

Journal Articles

Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity

Enli Liu, MD MS, Yijiu Tong, Gianpietro Dotti, MD, Barbara Savoldo, MD, Muharrem Muftuoglu, Kayo Kondo, PhD, Malini Mukherjee, Jordan S. Orange, MD PhD, Catherine Sobieski, Abdullah Alsuliman, Hila Shaim, MD, Nobuhiko Imahashi, MD PhD, Michael J. Keating, MD, Chitra M. Hosing, MD, Nina Shah, MD, William Wierda, MD PhD, Richard Champlin, MD, Elizabeth J. Shpall, MD, Katayoun Rezvani, MDPhD

Blood (2015) 126 (23): 3091.

https://doi.org/10.1182/blood.V126.23.3091.3091

Published: 2015

Journal Articles

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Basem M. William, MD, Marcos de Lima, MD, Betul Oran, MD, Richard Champlin, MD, Esperanza B Papadopoulos, MD, Sergio Giralt, MD, Bart L. Scott, MD, Joel Hetzer, PhD, Xiwei Wang, PhD, Eric Laille, MS, Barry S. Skikne, MD, Charles Craddock, MDPhD

Blood (2014) 124 (21): 990.

https://doi.org/10.1182/blood.V124.21.990.990

Published: 2014

Journal Articles

Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors

Marcos De Lima, MD, Sairah Ahmed, MD, Elizabeth J Shpall, MD, Gabriela Rondon, MD, Julienne Chen, Glenda G Woodworth, RN, Alexandre Chiattone, MD, Diem Thuy Chu, PA, Uday R Popat, MD, Susanna R Campos, MD, Amin M Alousi, MD, Chitra M Hosing, MD, Simrit Parmar, MD, Partow Kebriaei, MD, Issa F. Khouri, MD, Jorge E. Cortes, Jean-Pierre J Issa, MD, Richard Champlin, MD

Blood (2011) 118 (21): 3106.

https://doi.org/10.1182/blood.V118.21.3106.3106

Published: 2011

Journal Articles

Significant Changes in Inducible Cytokine Synthesis by Activated Peripheral Blood Leukocytes of Multiple Myeloma Patients Receiving Standard Dose Autologous Stem Cell Transplantation

Bang-Ning Lee, PhD, PA-C, Nina Shah, MD, Sergio Giralt, MD, Hui Gao, PhD, Evan N Cohen, BS, Lori Williams, PhD, Ibrahima Gning, Tito R Mendoza, PhD, Jane O Brown, RN, Valen E Johnson, PhD, Richard Champlin, MD, Charles S Cleeland, PhD, James M Reuben, PhD

Blood (2011) 118 (21): 5096.

https://doi.org/10.1182/blood.V118.21.5096.5096

Published: 2011

Journal Articles

Inotuzumab Ozogamicin (IO) Is An Effective Salvage Therapy That Allows for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Remission in Patients with Advanced Acute Lymphoblastic Leukemia (ALL)

Partow Kebriaei, MD, Kaci Wilhelm, Farhad Ravandi, MD, Rima M. Saliba, PhD, Marcos De Lima, MD, Stefan O Ciurea, MD, Laura L. Worth, MD, PhD, Susan O'Brien, MD, Deborah A. Thomas, MD, Richard Champlin, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 3102.

https://doi.org/10.1182/blood.V118.21.3102.3102

Published: 2011

Journal Articles

Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation

Yi Zhou, MD, PhD, Jeffrey L. Jorgensen, MD, PhD, Rima M Saliba, PhD, Sa A. Wang, MD, Gabriela Rondon, MD, Celina Ledesma, B.S., Borje S Andersson, MD, PhD, Marcos J de Lima, MD, Elizabeth J Shpall, MD, Uday Popat, M.D., Stefan O Ciurea, MD, Amin M Alousi, MD, Muzaffar Qazilbash, MD, Chitra M Hosing, MD, L. Jeffrey Medeiros, MD, Richard Champlin, MD, Partow Kebriaei, MD

Blood (2011) 118 (21): 3072.

https://doi.org/10.1182/blood.V118.21.3072.3072

Published: 2011

Journal Articles

High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies

Blood (2011) 118 (21): 3083.

https://doi.org/10.1182/blood.V118.21.3083.3083

Published: 2011

Journal Articles

Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL)

Paolo Anderlini, MD, Rima M Saliba, PhD, Celina Ledesma, B.S., Christina M Chancoco, Sandra Acholonu, Rosamar Valverde, Uday R Popat, MD, Chitra M Hosing, MD, Amin M Alousi, MD, Elizabeth J Shpall, MD, Yago Nieto, MD, PhD, Stefan O Ciurea, MD, Issa Khouri, MD, Richard Champlin, MD

Blood (2011) 118 (21): 3003.

https://doi.org/10.1182/blood.V118.21.3003.3003

Published: 2011

Journal Articles

Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)

Susan o'Brien, Deborah A. Thomas, MD, Maro Ohanian, M.D., Jeffrey L. Jorgensen, MD, PhD, Partow Kebriaei, MD, Elias Jabbour, Michael E. Rytting, MD, Sergernne York, RN, Farhad Ravandi, MD, Monica Kwari, BSN, Stefan Faderl, MD, Mary Beth Rios, RN, Jorge E. Cortes, Luis Fayad, MD, Robert Tarnai, MT, Sa A. Wang, MD, Richard Champlin, MD, Anjali S. Advani, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 875.

https://doi.org/10.1182/blood.V118.21.875.875

Published: 2011

Journal Articles

Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study

Borje S Andersson, MD, PhD, Marcos J de Lima, MD, Rima M Saliba, PhD, Elizabeth J Shpall, MD, Uday Popat, M.D., Roy Jones, MD, PhD, Yago Nieto, MD, PhD, Chitra M Hosing, MD, Partow Kebriaei, MD, Amin M Alousi, MD, Laura L. Worth, MD, PhD, Timothy Madden, Pharm.D., Alison Gulbis, Pharm.D., Julianne J Chen, Gabriela Rondon, MD, Patricia McAdams, RN, Becky McMullin, RN, Michael Andreeff, M.D., Ph.D., Richard Champlin, MD

Blood (2011) 118 (21): 892.

https://doi.org/10.1182/blood.V118.21.892.892

Published: 2011

Journal Articles

Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd

Issa F Khouri, MD, Rima M Saliba, PhD, Martin Korbling, MD, Amin M Alousi, MD, Uday R Popat, MD, Paolo Anderlini, MD, Stefan O Ciurea, MD, Partow Kebriaei, MD, Muzaffar H. Qazilbash, MD, Richard Champlin, MD, Roland L Bassett, Jr.

Blood (2011) 118 (21): 894.

https://doi.org/10.1182/blood.V118.21.894.894

Published: 2011

Journal Articles

Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90 yttrium Ibritumomab Tiuxetan ( 90 YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

Blood (2011) 118 (21): 662.

https://doi.org/10.1182/blood.V118.21.662.662

Published: 2011

Journal Articles

Combination of the Hypercvad Regimen with Dasatinib in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase of Chronic Myeloid Leukemia (CML-LB)

Theresa Liu-Dumlao, MD, Susan O'Brien, MD, Jorge E. Cortes, Deborah A. Thomas, MD, Stefan Faderl, MD, Elias Jabbour, Charles Koller, MD, Rebecca Garris, BSc, Partow Kebriaei, MD, Richard Champlin, MD, Gautam Borthakur, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, Farhad Ravandi, MD

Blood (2011) 118 (21): 2578.

https://doi.org/10.1182/blood.V118.21.2578.2578

Published: 2011

Journal Articles

CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia

Dongxia Xing, Ph. D., Alan G. Ramsay, PhD, William Decker, PhD, Dean A. Lee, MD, PhD, Simon Robinson, PhD, Nina Shah, MD, Simrit Parmar, M.D., Catherine M. Bollard, MD, FRACP, FRCPA, Chitra M Hosing, MD, Richard Champlin, MD, John G. Gribben, MD, DSc, Elizabeth J Shpall, MD

Blood (2011) 118 (21): 246.

https://doi.org/10.1182/blood.V118.21.246.246

Published: 2011

Journal Articles

Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Sairah Ahmed, MD, Heather Lin, PhD, Veera Baladandayuthapani, PhD, Mubeen A Khan, Gary Lu, MD, Gabriela Rondon, MD, Sofia Qureshi, Yvonne T Dinh, Qaiser Bashir, MD, Nina Shah, MD, Simrit Parmar, M.D., Chitra M Hosing, MD, Uday Popat, M.D., Sergio A Giralt, MD, Robert Z. Orlowski, MD, PhD, Jatin J Shah, MD, Richard Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2011) 118 (21): 333.

https://doi.org/10.1182/blood.V118.21.333.333

Published: 2011

Journal Articles

Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT)

Stefan O Ciurea, MD, Rima M. Saliba, PhD, Ulas D. Bayraktar, MD, Susan Xie, Gabriela Rondon, MD, Simrit Parmar, M.D., Partow Kebriaei, MD, Nivia Montes, PA, Manish Sharma, MD, Marina Konopleva, M.D., Ph.D., Yago Nieto, MD, PhD, Muzaffar H. Qazilbash, MD, Amin M Alousi, MD, Borje S Andersson, MD, PhD, Chitra M Hosing, MD, Elizabeth J Shpall, MD, Issa F. Khouri, MD, Marcos de Lima, MD, Richard Champlin, MD

Blood (2011) 118 (21): 320.

https://doi.org/10.1182/blood.V118.21.320.320

Published: 2011

Journal Articles

Chromosome 7 Abnormalities in Allogeneic Transplantation for AML and MDS

Vamsi Kota, MBBS, Rima M. Saliba, PhD, Ulas D. Bayraktar, MD, Amer Beitinjaneh, MD, Julianne J Chen, Simrit Parmar, M.D., Sergio A Giralt, MD, Gabriela Rondon, MD, Stefan O Ciurea, MD, Partow Kebriaei, MD, Muzaffar H Qazilbash, MD, Borje S Andersson, MD, PhD, Richard Champlin, MD, Marcos De Lima, MD

Blood (2011) 118 (21): 2037.

https://doi.org/10.1182/blood.V118.21.2037.2037

Published: 2011

Journal Articles

Allogeneic Stem Cell Transplantation for CML in Second Chronic Phase After Blast Crisis in the Tyrosine Kinase Inhibitor Era

Sairah Ahmed, MD, Alexandre Chiattone, MD, Roy Jones, MD, PhD, Elizabeth J Sphall, MD, Shatha Farhan, MD, Gabriela Rondon, MD, Yago Nieto, MD, PhD, Qaiser Bashir, MD, Julienne Chen, Issa F. Khouri, MD, Partow Kebriaei, MD, Paolo Anderlini, MD, Richard Champlin, MD, Marcos De Lima, MD

Blood (2011) 118 (21): 2039.

https://doi.org/10.1182/blood.V118.21.2039.2039

Published: 2011

Journal Articles

Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

Lisa Zipp, MS, Rima M Saliba, Ph.D., Rosamar Valverde, Grace-Julia Okoroji, Martin Korbling, MD, Barry I Samuels, MD, Lynne V. Abruzzo, MD, PhD, Amin M Alousi, MD, Borje S Andersson, MD, PhD, Chitra M Hosing, MD, Bill Erwin, MS, Paolo Anderlini, MD, Uday R Popat, MD, Partow Kebriaei, Homer A Macapinlac, MD, Richard Champlin, MD, Issa F. Khouri, MD

Blood (2011) 118 (21): 2005.

https://doi.org/10.1182/blood.V118.21.2005.2005

Published: 2011

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience

Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors

Significant Changes in Inducible Cytokine Synthesis by Activated Peripheral Blood Leukocytes of Multiple Myeloma Patients Receiving Standard Dose Autologous Stem Cell Transplantation

Inotuzumab Ozogamicin (IO) Is An Effective Salvage Therapy That Allows for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Remission in Patients with Advanced Acute Lymphoblastic Leukemia (ALL)

Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation

High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies

Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL)

Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)

Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study

Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd

Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90 yttrium Ibritumomab Tiuxetan ( 90 YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

Combination of the Hypercvad Regimen with Dasatinib in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase of Chronic Myeloid Leukemia (CML-LB)

CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia

Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT)

Chromosome 7 Abnormalities in Allogeneic Transplantation for AML and MDS

Allogeneic Stem Cell Transplantation for CML in Second Chronic Phase After Blast Crisis in the Tyrosine Kinase Inhibitor Era

Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only